It is made available under a CC-BY-NC-ND 4.0 International license .

1	Frequency and phenotype associations of rare variants in five monogenic cerebral small
2	vessel disease genes in 200,000 UK Biobank participants with whole exome sequencing
3	data
4	Amy C. Ferguson ¹ , Sophie Thrippleton ² , David E. Henshall ¹ , Ed Whittaker ² , Bryan Conway ³ ,
5	Malcolm MacLeod ⁴ , Rainer Malik ⁵ , Konrad Rawlik ⁶ , Albert Tenesa ^{1,6,7} , Cathie Sudlow ⁸ ,
6	Kristiina Rannikmäe ¹
7	¹ Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK
8	² Edinburgh Medical School, University of Edinburgh, Edinburgh, UK
9	³ Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh,
10	Edinburgh, UK
11	⁴ Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
12	5 Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany
13	⁶ The Roslin Institute, University of Edinburgh, Edinburgh, UK
14	⁷ MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General
15	Hospital, Edinburgh, UK
16	⁸ BHF Data Science Centre, Health Death Research UK, London, UK
17	Corresponding authors: Amy C. Ferguson, afergus8@ed.ac.uk; Kristiina Rannikmäe,
18	kristiina.rannikmae@ed.ac.uk
19	
20	Abstract
21	Based on previous case reports and disease-based cohorts, a minority of patients with cerebral small
22	vessel disease (cSVD) have a monogenic cause, with many also manifesting extra-cerebral

- 23 phenotypes. We investigated the frequency, penetrance, and phenotype associations of rare
- 24 variants in cSVD genes in UK Biobank (UKB), a large population-based study.

25	We used a systematic review of previous literature and ClinVar to identify putative pathogenic rare
26	variants in CTSA, TREX1, HTRA1, COL4A1/2. We mapped phenotypes previously attributed to these
27	variants (phenotypes-of-interest) to disease coding systems used in UKB's linked health data from
28	UK hospital admissions, death records and primary care. Among 199,313 exome-sequenced UKB
29	participants, we assessed: the proportion of participants carrying \geq 1 variant(s); phenotype-of-
30	interest penetrance; and the association between variant carrier status and phenotypes-of-interest
31	using a binary (any phenotype present/absent) and phenotype burden (linear score of the number of
32	phenotypes a participant possessed) approach.
33	Among UKB participants, 0.5% had \geq 1 variant(s) in studied genes. Using hospital admission and
34	death records, 4-20% of variant carriers per gene had an associated phenotype. This increased to 7-
35	55% when including primary care records. Only COL4A1 variant carrier-status was significantly
36	associated with having \geq 1 phenotype-of-interest and a higher phenotype score (OR=1.29, p=0.006).
37	While putative pathogenic rare variants in monogenic cSVD genes occur in 1:200 people in the UKB
38	population, only around half of variant carriers have a relevant disease phenotype recorded in their
39	linked health data. We could not replicate most previously reported gene-phenotype associations,
40	suggesting lower penetrance rates, overestimated pathogenicity and/or limited statistical power.
41	
42	Introduction
43	Cerebral small vessel disease (cSVD) refers to a variety of pathological processes impacting the
44	brain's small arteries, arterioles, venules, and capillaries ¹ . It is estimated that 20% of ischaemic
45	strokes, and most haemorrhagic strokes, are caused by cSVD. cSVD is also the most frequent
46	pathology underlying vascular dementia and vascular cognitive impairment ²⁻⁴ .

An unknown minority of cSVD cases are considered monogenic, i.e., caused by a pathogenic
variant(s) in one of several genes. While *NOTCH3* (implicated in cerebral autosomal dominant

49	arteriopathy with subcortical infarcts and leukoencephalopathy, CADASIL) is the best known of
50	these, since its first description in 1996 ⁵ , several additional cSVD genes have been identified.
51	Examples include CTSA, TREX1, HTRA1, COL4A1 and COL4A2, but there are additional genes where
52	cSVD is either not the primary associated phenotype (e.g., ADA2 and GLA) or to date there is weaker
53	causal evidence (e.g., FOXC1, PITX2, COLGALT1) ² . Many monogenic cSVD cases also show
54	overlapping systemic and neurological features ^{2,6,7} . Our recent systematic literature review of 2800
55	individual cases carrying putative pathogenic variants in six cSVD genes found that several
56	monogenic cSVD genes are associated with a range of extra-cerebral phenotypes affecting ocular,
57	renal, hepatic, muscle, and haematological systems ⁶ . These extra-cerebral phenotypes can be
58	diagnostically important through contributing to clinically recognisable syndromes informing genetic
59	testing, as well as provide mechanistic insights into the pathophysiology of cSVD ^{6,8,9} .
60	To date, our knowledge of monogenic cSVD variants' frequency, penetrance and phenotype
61	associations comes primarily from case reports, small case series and family pedigree studies ⁶ . The
62	resulting data is therefore affected by various biases, including investigation bias (patients with
63	clinically severe and previously described manifestations are more likely to have genetic testing and
64	undergo investigations for known expected associated pathologies if a pathogenic variant in a
65	relevant gene is found), publication bias (clinicians/researchers are more likely to publish a case
66	report/series about clinically severely and/or unusually affected patients), and reporting bias
67	(published case reports/series tend to discuss previously reported or particularly unusual clinical
68	signs and symptoms rather than describe case's health in an unbiased and systematic way) ^{6,10,11} .
69	There have also been few disease-based studies exploring rare variation in cSVD genes in apparently
70	sporadic cases of cSVD ¹²⁻¹⁵ , but the population frequency and clinical consequences of these variants
71	remains unknown.

Data from large-scale population-based studies collecting health outcomes in a systematic, unbiased
 way would provide additional information on the frequency and clinical impact of monogenic cSVD

74 rare variants in a different setting. Investigating routinely collected, linked, healthcare records would

75 overcome some of the limitations of previous studies.

76 The UK Biobank (UKB) cohort is a prospective study of approximately 500,000 UK residents recruited

- from 2006-2010, aged 40-69 at the time of recruitment. It has extensive phenotypic information
- 78 derived from linked healthcare and death record data, with whole exome sequencing (WES) data
- 79 available for around 200,000 participants as of October 2020. Full details of UKB have been
- 80 previously described^{16–18}.
- 81 We aimed to use UKB to assess the population frequency of putative pathogenic rare genetic
- 82 variation in five known monogenic cSVD genes CTSA, TREX1, HTRA1, COL4A1 and COL4A2
- 83 (excluding *NOTCH3* since it has already been investigated in UKB¹⁹). We studied their apparent
- 84 penetrance (i.e., the proportion of participants with a variant manifesting a relevant cerebral and/or

85 extra-cerebral clinical phenotype) and gene-phenotype associations in the general population, not

selected on the basis of disease or disease risk (Figure 1).

87 Methods

88 Study population

89 Our population of interest comprised the 200,603 UKB participants with WES data available from 90 October 2020. We excluded: (i) related individuals based on genetic relatedness pairings as provided 91 by UKB Field 22011, excluding one individual from each related pair but preferentially retaining 92 participants carrying a variant-of-interest; and (ii) participants with sex mismatch (reported sex did 93 not match genetic recorded sex). After these quality control exclusions, our study population 94 comprised 199,313 UKB participants. The following data was available for the whole sample: (i) WES; 95 (ii) coded hospital inpatient admissions and death record data [UKB Fields 41270, 40001, 40002]; (iii) 96 baseline characteristics (age at last follow up on March 2020 [derived from UKB Fields 34 and 52],

97 sex [UKB Fields 31 and 22001], self-reported ethnicity [UKB Field 21000], Townsend deprivation

98 index – a marker of socio-economic deprivation [UKB Field 189]). Coded primary care data [UKB Field

99 42040] was also available for a 48% subset (95,459 participants).

100 Variant selection

- 101 We identified putative pathogenic rare variants in CTSA, TREX1, HTRA1, COL4A1 and COL4A2, which
- 102 we refer to as 'variants-of-interest'. We defined putative pathogenic rare variants as variants that
- 103 are: (i) reported as causing disease in the published literature based on our systematic review
- 104 (SysRev variants)⁶; and/or (ii) reported as "pathogenic" or "likely pathogenic" in the ClinVar database

105 (ClinVar variants)²⁰; and (iii) have a minor allele frequency (MAF) <1% in the UK Biobank. An

106 exception to this were TREX1 and CTSA genes, which in addition to monogenic cSVD are also

107 associated with other specific monogenic disorders (Aicardi-Goutieres syndrome and

108 Galactosialidosis, respectively)^{21–23}. Hence for these two genes, variants reported to be specific for

109 conditions other than cSVD were excluded. We used the Ensembl variant effect predictor (VEP) to

110 estimate the pathogenicity and protein impact of variants-of-interest, based on SIFT, PolyPhen and

111 SnpEff²⁴.

112 **Phenotype selection and mapping**

113 We first compiled a list of cerebral and extra-cerebral phenotypes previously attributed to CTSA, 114 TREX1, HTRA1, COL4A1 and COL4A2 variants-of-interest. We included phenotypes reported as being 115 associated with these genes in Online Mendelian Inheritance in Man (OMIM) and/or in our recent 116 systematic review^{6,23}, from here-on referred to as phenotypes-of-interest. We mapped these 117 phenotypes to the disease-coding systems used for recording hospital inpatient admissions, death 118 record and primary care data in the UKB, i.e., International Classifications of Diseases – 10 (ICD-10), 119 Read V2 and Read V3 disease-coding systems. Further detail regarding the mapping process is 120 provided in the Supplemental Methods.

121 Data analyses

It is made available under a CC-BY-NC-ND 4.0 International license .

122 Assessing variant carrier frequencies in the UKB and their demographic characteristics

- 123 Using Functional Equivalence (FE)-derived PLINK files^{17,18}, we calculated the total number and
- 124 proportion of UKB participants with ≥1 variant-of-interest (from here-on referred to as "variant
- 125 carriers"). We used Chi-squared and two sample t-tests to assess differences between variant
- 126 carriers and non-carriers in age, sex, Townsend deprivation index, ethnicity, and the presence of
- 127 vascular risk factors (0-1 versus ≥2 risk factors described in Supplemental Table 6 legend).
- 128 Assessing the proportion of variant carriers with phenotypes-of-interest
- 129 As a measure of genetic variant penetrance, we calculated the proportion of variant carriers with ≥ 1
- 130 phenotype-of-interest in the hospital inpatient admissions and/or death record data for the whole
- 131 study population, and in hospital admissions, death record and/or primary care data for the 48%
- subset of the study population with linked primary care data. We further explored the proportion of
- 133 variant carriers with a stroke diagnosis, one of the main clinical manifestations of cSVD²⁻⁴.
- 134 Assessing whether variant carrier status is associated with phenotypes-of-interest
- 135 We tested for statistically significant associations between variant carrier status and phenotypes-of-
- 136 interest by gene. We undertook the primary analyses in the whole cohort and repeated these as
- 137 secondary analyses in the subgroup with primary care data.
- 138 Association with phenotype-of-interest status

139 For each of the five genes, we checked for differences in the proportion of participants with any

- 140 phenotype-of-interest, and with stroke specifically, among variant carriers compared to non-carriers.
- 141 We used a Chi-squared test and set a Bonferroni-corrected significance p-value of <0.01 (corrected
- 142 for the 5 gene-level tests).
- 143 Association with phenotype burden (phenotype score)

144 We assessed for difference in overall phenotype burden between variant carriers and non-carriers,

- 145 creating for each gene and participant: binary variant scores using an unweighted gene-based
- 146 collapsing approach²⁵ (with carriers given a score of 1 and non-carriers a score of 0); and unweighted

147	phenotype scores (based on the number of the phenotypes-of-interest associated with the gene).
148	For example, HTRA1 is associated with 6 phenotypes-of-interest and a participant could therefore
149	have a minimum HTRA1 phenotype score of 0 (if they did not manifest any phenotypes-of-interest)
150	and a maximum score of 6 (if they manifested all 6 phenotypes-of-interest) (Supplemental Table 1).
151	We used Poisson regression (due to the phenotype scores being based on exact counts) to
152	investigate, for each gene, the association between carrying a rare variant and phenotype score
153	including age at last follow-up, sex, Townsend index, and 20 genetic principal components (PCs) as
154	covariates. We used a Bonferroni-corrected p-value threshold of <0.01 to determine significance
155	(corrected for 5 gene-level tests).
156	For primary analyses we additionally: (i) adjusted for vascular risk factors ^{26,27} (Supplemental Table 6
157	legend); (ii) checked for interactions between variant carrier status with sex and ethnicity; and (iii)
158	ran leave-one-out sensitivity analyses, where each phenotype was removed from the phenotype
159	score one-by-one (using logistic instead of Poisson regression in case of COL4A2 which only had two
160	phenotypes-of-interest to start with).
161	Results
161 162	Results We identified a total 253 variants-of-interest across the five genes to investigate in UKB: 145
161 162 163	Results We identified a total 253 variants-of-interest across the five genes to investigate in UKB: 145 exclusively from SysRev, 48 exclusively from ClinVar, and 60 from both sources. We found a total of
161 162 163 164	Results We identified a total 253 variants-of-interest across the five genes to investigate in UKB: 145 exclusively from SysRev, 48 exclusively from ClinVar, and 60 from both sources. We found a total of 37 variants present in ≥1 of the 199,313 included UKB participants: 24 exclusively from SysRev, 2
161 162 163 164 165	Results We identified a total 253 variants-of-interest across the five genes to investigate in UKB: 145 exclusively from SysRev, 48 exclusively from ClinVar, and 60 from both sources. We found a total of 37 variants present in ≥1 of the 199,313 included UKB participants: 24 exclusively from SysRev, 2 exclusively from ClinVar, and 11 from both sources, but these did not include any <i>TREX1</i> or <i>CTSA</i>
161 162 163 164 165 166	ResultsWe identified a total 253 variants-of-interest across the five genes to investigate in UKB: 145exclusively from SysRev, 48 exclusively from ClinVar, and 60 from both sources. We found a total of37 variants present in ≥1 of the 199,313 included UKB participants: 24 exclusively from SysRev, 2exclusively from ClinVar, and 11 from both sources, but these did not include any <i>TREX1</i> or <i>CTSA</i> variants-of-interest. The number of variants represented in UKB varied for each gene, ranging from 5
161 162 163 164 165 166 167	ResultsWe identified a total 253 variants-of-interest across the five genes to investigate in UKB: 145exclusively from SysRev, 48 exclusively from ClinVar, and 60 from both sources. We found a total of37 variants present in ≥1 of the 199,313 included UKB participants: 24 exclusively from SysRev, 2exclusively from ClinVar, and 11 from both sources, but these did not include any <i>TREX1</i> or <i>CTSA</i> variants-of-interest. The number of variants represented in UKB varied for each gene, ranging from 5(COL4A2) to 17 (COL4A1). Across these variants, MAF in UKB ranged from 0.0005-0.14%.
161 162 163 164 165 166 167 168	ResultsWe identified a total 253 variants-of-interest across the five genes to investigate in UKB: 145exclusively from SysRev, 48 exclusively from ClinVar, and 60 from both sources. We found a total of37 variants present in ≥1 of the 199,313 included UKB participants: 24 exclusively from SysRev, 2exclusively from ClinVar, and 11 from both sources, but these did not include any <i>TREX1</i> or <i>CTSA</i> variants-of-interest. The number of variants represented in UKB varied for each gene, ranging from 5(COL4A2) to 17 (COL4A1). Across these variants, MAF in UKB ranged from 0.0005-0.14%.(Supplemental tables 2 and 3).

to be missense or nonsense mutations. Of the remaining two SysRev variants, one was in the 5'

171 untranslated region and the other an intronic splice donor variant. SnpEff predicted the nonsense

mutations and the colling department to have high impact, while all but one of the remaining

172	mutations and the splice donor variant to have high impact, while all but one of the remaining
173	variants were of moderate impact. Overall, 21/37 variants (50% SysRev; 50% ClinVar, 73% both
174	sources) were predicted to have probably damaging and deleterious impacts on protein structure
175	and function (Supplemental Table 4).
176	We identified 2 to 12 phenotypes-of-interest per gene (Supplemental table 1). When mapping these
177	to disease coding systems, the number of codes per phenotype varied widely, ranging from 6 codes
178	for dry mouth to 173 codes for degenerative spine disease (Supplemental code list).
179	Assessing variant carrier frequencies in the UKB and their demographic characteristics
180	Among 199,313 UKB participants, 1,050 participants (0.5%) had ≥1 variant-of-interest, resulting in
181	234 HTRA1, 481 COL4A1 and 336 COL4A2 variant carriers, with one participant carrying a variant in
182	both HTRA1 and COL4A1. When variant carriers were not preferentially selected from related pairs,
183	their overall frequency remained the same. Most variant carriers (96%; 1,003/1,050) possessed a

184 SysRev variant, 0.3% (3/1,050) a ClinVar variant, and 4% (44/1,050) a variant represented in both

185 SysRev and ClinVar (Supplemental tables 2 and 3).

186 The mean age (at last follow-up) of all included UKB participants was 68.2 years. The mean

187 Townsend deprivation index was -1.34 and 55% of participants were female. There was no

188 significant difference in age at last follow-up, sex, or presence of vascular risk factors between

189 variant carriers and non-carriers. Carriers had significantly higher levels of deprivation than non-

carriers (mean Townsend index = -0.44 vs -1.34, p<2.2x10⁻¹⁶), and were more likely to be of non-190 191 white ethnicity $(p<2.2x10^{-16})$ (Table 1).

192 Based on these findings, we performed post-hoc analyses comparing variant-carriers and non-

193 carriers in terms of: (i) mean Townsend index stratified by manifestation of a phenotype-of-interest;

and, (ii) Townsend index breakdown by quintiles derived from the QResearch database^{28,29}, 194

195 comparing the frequency of phenotypes-of-interest. Variant-carriers had significantly higher levels of

196 deprivation compared to non-carriers regardless of whether or not they manifested a phenotype-of-

197	interest (-0.31 vs -1.07, p=0.0004 and -0.44 vs -1.4, p<2.2x10 ⁻¹⁶ , respectively). Comparing the
198	frequency of participants manifesting a phenotype, among variant-carriers it was similar in the least
199	and most deprived quintiles (23% vs 24%), whereas among non-carriers, the least deprived had a
200	lower frequency compared to the most deprived (17% vs 23%) (Supplemental Table 5).
201	Exploring the ethnicity distribution further, majority of <i>HTRA1</i> and <i>COL4A1</i> variant carriers (\geq 97%)
202	were of self-reported White ethnicity. For COL4A2, however, 57% (190/336) of variant-carriers were
203	of self-reported Black ethnicity, driven by 2 variants c.3448C>A and c.5068G>A present in 1.2% and
204	4.7% of Black participants, respectively. A further 14% of COL4A2 variant-carriers were of mixed and
205	other ethnic groups (Table 2).
206	Assessing the proportion of variant carriers with phenotypes-of-interest
207	The proportion of variant carriers (N=1,050) with \geq 1 phenotype-of-interest in the hospital inpatient
208	admissions and/or death record data was: HTRA1 9% (21/234); COL4A1 20% (95/481); and COL4A2
209	4% (15/336) (Figure 2a). This proportion increased when we explored the smaller subset of the
210	variant carriers for whom primary care data was also available (N = 484): HTRA1 55% (64/117);
211	COL4A1 40% (93/236); and COL4A2 7% (9/132) (Figure 2b). Among variant carriers manifesting a
212	phenotype-of-interest, stroke was not always the most common phenotype: HTRA1 13% to 52%,
213	COL4A1 15% to 19% and COL4A2 93-100% (Figure 2a, Figure 2b).
214	Assessing whether variant carrier status is associated with phenotypes-of-interest
215	Association with phenotype-of-interest status
216	For phenotypes-of-interest in the hospital inpatient admissions and/or death record data, a higher
217	proportion of COL4A1 variant carriers compared to non-carriers had a COL4A1-related phenotype
218	(20% in carriers vs 15% in non-carriers, p=0.01). We found no significant associations for HTRA1 and
219	COL4A2, and no significant associations for any gene in the secondary analyses also including

- 220 primary care data. There was also no significant difference in the proportion of stroke cases seen
- 221 between carriers and non-carriers for any of the genes.

It is made available under a CC-BY-NC-ND 4.0 International license .

222 Association with phenotype burden (phenotype score)

- 223 COL4A1 carriers also had a greater phenotype score compared to non-carriers (OR=1.29, p=0.006).
- 224 We found no significant associations for *HTRA1* and *COL4A2*, nor for any gene in the secondary
- analyses including primary care data. (Figure 3).
- 226 The associations remained similar after adjusting the primary analyses for the presence of vascular
- risk factors (Supplemental Table 6). We found no significant interactions with sex (*HTRA1* p=0.41;
- 228 COL4A1 p=0.14; COL4A2 p=0.49) and ethnicity (HTRA1 p=0.60; COL4A1 p=0.88; COL4A2 p=0.19) for
- any gene.
- 230 Leave-one-out sensitivity analyses did not change the results significantly for HTRA1 or COL4A2
- 231 (Supplemental Figure 1). For COL4A1, removing cataract, migraine or stroke from the phenotype
- score rendered the association no longer significant, suggesting these phenotypes are important in
- driving the association seen in the primary analyses (Figure 4).

234 Discussion

- 235 We found that while 1:200 UKB participants carry a previously reported putative pathogenic rare
- variant in one of the five cSVD genes included in our study, only 4% to 20% of variant-carriers per
- 237 gene had an associated phenotype recorded in their hospital admission/death records, and this rose
- 238 moderately to 7% to 55% when also including primary care records. COL4A1 variant carrier status
- 239 was associated with having phenotypes-of-interest compared to non-carriers, but we did not see
- significant associations with expected phenotypes for other genes.
- 241 We are not aware of previous studies investigating these five genes in a population-based setting.
- 242 There has however been a study of another monogenic cSVD gene, which demonstrated that ~1:450
- 243 UKB participants carry a putative pathogenic (i.e., cysteine-altering) variant *NOTCH3*¹⁹. Among the
- 244 few disease-based studies exploring rare variation in cSVD genes in apparently sporadic cases, one
- 245 large study found that ~1:70 lacunar stroke patients had a monogenic cause¹³. However, this study

246	included only patients with stroke (one of several manifestations of cSVD), excluded already
247	diagnosed monogenic cSVD cases and involved an overlapping but not identical set of genes with
248	different definition of putative pathogenicity compared to our study, limiting direct comparisons.
249	We did not find any carriers of CTSA or TREX1 putative pathogenic rare variants in UKB. Potential
250	reasons include: (i) variants in these genes are extremely rare in general and/or rare in a population-
251	based setting owing to their severe phenotype manifestations, this is particularly relevant for TREX1
252	where the majority of variants were frameshifts which were not as highly represented in UKB WES
253	data compared to single nucleotide variants ¹⁸ ; (ii) the overall number of variants-of-interest in these
254	genes was smaller and they are not present in UKB by chance.
255	We found a significantly higher level of deprivation among variant-carriers compared to non-
256	carriers. Further post-hoc analyses suggested that this difference is not explained by variant-carriers
257	manifesting a disease phenotype. Exploring the Townsend deprivation index distribution by quintiles
258	suggested that carrying a putative pathogenic rare variant increases the chances of having a
259	phenotype among the least deprived, but not among the most deprived participants. One possible
260	explanation might be that participants in the most deprived group have an already increased risk
261	due to environmental factors, whereas in the least deprived group, genetic variation plays a more
262	important role. However, this was not the primary aim of our study and requires further research.
263	The majority of COL4A2 carriers in UKB were of non-White self-reported ethnic group. The two
264	genetic variants driving the frequency among non-White participants had previously been reported
265	in the literature as causing intracerebral haemorrhage in persons of White Hispanic and African
266	American background ³⁰ . Earlier studies have focused mainly on investigating European populations,
267	while case reports and series are often missing ethnicity information ^{6,13,31,32} , leaving monogenic cSVD
268	and relevant genetic variation prevalence estimates among non-White ethnicities largely
269	unknown ^{13,32} . One study which did investigate this in the Genome Aggregation Database among
270	seven ethnic groups did not find a similar enrichment of COL4A2 carriers among participants of Black

271	and other ethnicities, although interestingly COL4A1 pathogenic variants were most prevalent
272	among Africans/African-Americans ³¹ . Furthermore, epidemiological studies have demonstrated
273	racial and ethnic differences in cSVD manifestations and burden, which may have a genetic
274	component ³³ . These findings underline the importance of extending future genetic studies to include
275	a broader range of ethnic groups.
276	Evidence from the existing literature summarised in a systematic review demonstrated a higher
277	proportion of variant carriers manifesting a relevant phenotype compared to our study, with
278	estimates of 59% for COL4A2, 75% for COL4A1, and 77% for HTRA1 ⁶ . Considering the mean age of
279	UKB participants is older than the mean age of individuals included in the systematic review ⁶ , it is
280	unlikely this difference is explained by limited duration of follow-up in UKB and our analysis
281	capturing participants who will go on to develop the phenotypes in the future. Our results
282	suggesting lower frequency of phenotypic manifestations in carriers of variants associated with cSVD
283	in a population-based setting are in keeping with findings from other monogenic disease
284	investigations. Similar results have been shown for monogenic diabetes and CADASIL ^{19,34–36} ,
285	demonstrating ascertainment context is crucial when interpreting the consequences of monogenic
286	variants. This has important implications for genetic screening and counselling in the clinical setting.
287	We identified a significant association for COL4A1 between variant carrier status and phenotype
288	score. Leave-one-out subgroup analyses indicated that migraine, cataract, and stroke contributed
289	most to the association seen. We did not find significant associations between HTRA1/COL4A2 and
290	phenotypes previously attributed to putative pathogenic variants in those genes. This may suggest
291	that these variants: (i) have reduced penetrance; (ii) have variable expressivity; (iii) are not all
292	pathogenic despite previous reports; (iv) have previously been incorrectly associated with certain
293	disease-phenotypes in the literature and OMIM; and/or (v) were not present in large enough
294	numbers limiting statistical power.

295 Our variants-of-interest had evidence from the literature and ClinVar to support that they are 296 pathogenic. Using Ensemble VEP to further investigate these variants generally corroborated this 297 assumption - all but one had a moderate or high impact according to SnpEff and about two thirds 298 were bioinformatically predicted to be deleterious and probably damaging to protein structure and 299 function. 300 Our study has several strengths. By using all available sources of routinely collected health data, we 301 were able to systematically capture the full range of phenotypes previously reported to be 302 associated with monogenic cSVDs, both cerebral and extra-cerebral. This approach limits several of 303 the biases which affect case-reports and series and is feasible among large numbers of participants. 304 Our study is the first to explore rare variation in these five genes in a population-based setting, and 305 as such provides valuable information on their frequency and spectrum of clinical consequences, 306 supplementing existing knowledge derived mainly from case-reports and series. This in turn can 307 inform clinicians of various specialties and clinical geneticist in selecting patients to test and when 308 counselling variant carriers in the clinical setting.

309 There are also limitations which need to be considered. Firstly, we used routinely collected coded 310 administrative health data to identify disease-phenotypes. While we made significant efforts to map 311 the phenotypes-of-interest systematically and transparently to relevant disease codes, driven by 312 clinically informed selection, these coded data are likely to identify some false-positive and miss 313 true-positive cases. Also, it was more challenging to map some phenotypes than others, and some 314 health conditions (e.g., alopecia, migraine or muscle cramps) are less likely to lead the person to 315 seek medical help and hence be captured by the coded data. Secondly, the UKB population is highly likely affected by the 'healthy volunteer bias'¹⁶, with clinically severely affected variant carriers less 316 317 likely to enrol in the first place. Hence the variants identified among the UKB population may be 318 those with lower overall genetrance, variable expressivity, and weaker evidence of pathogenicity. 319 Thirdly, even when collapsing the variants across each gene, statistical power for detecting small and

320	moderate variant-level	genotype-p	henotype ass	ociation effects	remained low.	Fourth, routin
520	mouchate variant level	Schotype p	nenotype ass	ociation criters	remained low.	rourn, roun

- 321 collected administrative disease codes did not provide data on cerebral radiological features of UKB
- 322 participants, which is an important (and sometimes the only) manifestation of cSVD⁴.
- 323 Future studies will be required to extend these findings to other populations, aiming to better
- 324 understand and minimise healthy volunteer biases and assessing a broader range of ages and socio-
- 325 economic- and ethnic groups with even larger sample sizes. As methods of disease identification
- from routinely collected health data develop further, this will also allow more comprehensive and
- 327 reliable capture of phenotypes-of-interest. Future work could also explore all rare variants in these
- 328 genes, stratifying them by level of evidence for pathogenicity and using the richness of the routinely
- 329 collected health data to undertake phenome-wide association studies.
- 330 In conclusion, putative pathogenic rare variants in five monogenic cSVD genes occur in the
- population at a frequency of 1:200, but only up to half of variant carriers have a relevant disease
- 332 phenotype recorded in their linked health data. We could not replicate most previously reported
- 333 gene-phenotype associations, suggesting lower penetrance rates, overestimated pathogenicity
- and/or limited statistical power. We also highlight the importance of considering the wider spectrum
- of phenotypic manifestations in cSVD.
- 336 Supplemental data
- Supplemental data includes six tables and one figure displaying additional variant information andresults.
- Supplemental methods: details the methodology used to map the phenotypes-of-interest to ICD-10
 and Read v2/v3 codes.
- 341 Supplemental code list: contains the ICD-10 and Read v2/v3 code lists used to derive the
- 342 phenotypes-of-interest for this study.

343 Declaration of interests

344 The authors declare no competing interests.

It is made available under a CC-BY-NC-ND 4.0 International license .

345 Acknowledgements

- 346 AF is funded by BHF award RE/18/5/34216. KR and AF are funded by Health Data Research UK
- 347 Rutherford fellowship (MR/S004130/1). AT is funded by HDR-UK award HDR-9004 and HDR-9003.
- 348 We would like to acknowledge Professor Martin Dichgans from the Institute for Stroke and
- 349 Dementia Research in Munich Germany for his input at the earlier stages of conception of this work.

350 Data and code availability

- 351 Original phenotype and genotype data is available from UK Biobank¹⁶. ICD-10 and Read v2/3 code
- 352 lists used for analysis are available in the Appendix (Supplemental code list).

353

354 References

- Pantoni, L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to
 therapeutic challenges. *The Lancet Neurology* vol. 9 689–701 (2010).
- Marini, S., Anderson, C. D. & Rosand, J. Genetics of Cerebral Small Vessel Disease. *Stroke* 51,
 12–20 (2020).
- 359 3. Markus, H. S. & Schmidt, R. Genetics of Vascular Cognitive Impairment. *Stroke* 50, 765–772
 360 (2019).
- Wardlaw, J. M., Smith, C. & Dichgans, M. Small vessel disease: mechanisms and clinical
 implications. *Lancet Neurol.* 18, 684–696 (2019).
- Joutel, A. et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing
 stroke and dementia. Nature vol. 383 http://www.nature. (1996).
- 365 6. Rannikmäe, K. *et al.* Beyond the Brain: Systematic Review of Extracerebral Phenotypes
- Associated with Monogenic Cerebral Small Vessel Disease. *Stroke* **51**, 3007–3017 (2020).
- 367 7. Yamamoto, Y., Craggs, L., Baumann, M., Kalimo, H. & Kalaria, R. N. Review: Molecular

It is made available under a CC-BY-NC-ND 4.0 International license .

- 368 genetics and pathology of hereditary small vessel diseases of the brain. Neuropathol. Appl.
- 369 Neurobiol. **37**, 94–113 (2011).
- 370 8. Sargurupremraj, M. *et al.* Cerebral small vessel disease genomics and its implications across
 371 the lifespan. *Nat. Commun.* **11**, (2020).
- 372 9. Søndergaard, C. B., Nielsen, J. E., Hansen, C. K. & Christensen, H. Hereditary cerebral small
- 373 vessel disease and stroke. Clin. Neurol. Neurosurg. 155, 45–57 (2017).
- Murad, M. H., Sultan, S., Haffar, S. & Bazerbachi, F. Methodological quality and synthesis of
 case series and case reports. *BMJ Evidence-Based Med.* 23, 60–63 (2018).
- 11. Riley, D. S. et al. CARE guidelines for case reports: explanation and elaboration document. J.
- 377 Clin. Epidemiol. **89**, 218–235 (2017).
- Tan, R., Traylor, M., Rutten-Jacobs, L. & Markus, H. New insights into mechanisms of small
 vessel disease stroke from genetics. *Clin. Sci.* 131, 515–531 (2017).
- 380 13. Tan, R. Y. Y. *et al.* How common are single gene mutations as a cause for lacunar stroke?
- 381 Neurology 93, e2007–e2020 (2019).
- 14. Chong, M. *et al.* Mendelian Genes and Risk of Intracerebral Hemorrhage and Small-Vessel
 Ischemic Stroke in Sporadic Cases. *Stroke* 48, 2263–2265 (2017).
- Weng, Y.-C. *et al.* COL4A1 mutations in patients with sporadic late-onset intracerebral
 hemorrhage. *Ann. Neurol.* **71**, 470 (2012).
- Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature*562, 203–209 (2018).
- Jia, T., Munson, B., Lango Allen, H., Ideker, T. & Majithia, A. R. Thousands of missing variants
 in the UK Biobank are recoverable by genome realignment. *Ann. Hum. Genet.* 84, 214–220
 (2020).

It is made available under a CC-BY-NC-ND 4.0 International license .

- 18. Van Hout, C. V et al. Exome sequencing and characterization of 49,960 individuals in the UK
- 392 Biobank. *Nature* **586**, 749 (2020).
- 393 19. Cho, B. P. H. et al. NOTCH3 variants are more common than expected in the general
- 394 population and associated with stroke and vascular dementia: an analysis of 200 000
- 395 participants. J. Neurol. Neurosurg. Psychiatry 92, 694–701 (2021).
- 396 20. Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting
- 397 evidence. Nucleic Acids Res. 46, D1062 (2018).
- 398 21. Yang, Y. G., Lindahl, T. & Barnes, D. E. Trex1 Exonuclease Degrades ssDNA to Prevent Chronic
- 399 Checkpoint Activation and Autoimmune Disease. Cell 131, 873–886 (2007).
- 400 22. Caciotti, A. *et al.* Galactosialidosis: review and analysis of CTSA gene mutations. *Orphanet J.*
- 401 *Rare Dis.* **8**, 114 (2013).
- 402 23. OMIM Online Mendelian Inheritance in Man. https://omim.org/.
- 403 24. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016 171 17, 1–14
- 404 (2016).
- 405 25. Povysil, G. *et al.* Rare-variant collapsing analyses for complex traits: guidelines and
 406 applications. *Nat. Rev. Genet.* doi:10.1038/s41576-019-0177-4.
- 407 26. Boehme, A. K., Esenwa, C. & Elkind, M. S. V. Stroke Risk Factors, Genetics, and Prevention.
 408 *Circulation Research* vol. 120 472–495 (2017).
- 409 27. Hauer, A. J. *et al.* Age-specific vascular risk factor profiles according to stroke subtype. *J. Am.*410 *Heart Assoc.* 6, (2017).
- 411 28. Home QResearch. https://www.qresearch.org/.
- 412 29. Julia Hippisley-Cox. Cut offs for Townsend quintiles in England and Wales and QResearch.
- 413 https://www.qresearch.org/media/1056/cut-offs-for-townsend-quintiles-in-england-and-

It is made available under a CC-BY-NC-ND 4.0 International license .

414 wales-and-gresearch.pdf (2011).

- 415 30. Jeanne, M. et al. COL4A2 Mutations Impair COL4A1 and COL4A2 Secretion and Cause
- 416 Hemorrhagic Stroke. *Am. J. Hum. Genet.* **90**, 91 (2012).
- 417 31. Grami, N. et al. Global Assessment of Mendelian Stroke Genetic Prevalence in 101 635
- 418 Individuals from 7 Ethnic Groups. *Stroke* 1290–1293 (2020)
- 419 doi:10.1161/STROKEAHA.119.028840.
- 420 32. Kilarski, L. L. *et al.* Prevalence of CADASIL and fabry disease in a cohort of MRI defined
 421 younger onset Lacunar Stroke. *PLoS One* **10**, e0136352 (2015).
- 422 33. Castello, J. P. et al. Contribution of Racial and Ethnic Differences in Cerebral Small Vessel
- 423 Disease Subtype and Burden to Risk of Cerebral Hemorrhage Recurrence. *Neurology* 96,
- 424 e2469–e2480 (2021).
- 425 34. Mirshahi, U. L. et al. The penetrance of age-related monogenic disease depends on
- 426 ascertainment context. *medRxiv* 2021.06.28.21259641 (2021)
- 427 doi:10.1101/2021.06.28.21259641.
- 428 35. Rutten, J. W. *et al.* Broad phenotype of cysteine-altering NOTCH3 variants in UK Biobank:
- 429 CADASIL to nonpenetrance. *Neurology* **95**, e1835–e1843 (2020).
- 430 36. Hack, R. J. *et al.* Cysteine-Altering NOTCH3 Variants Are a Risk Factor for Stroke in the Elderly
 431 Population. *Stroke* 3562–3569 (2020) doi:10.1161/STROKEAHA.120.030343.
- 432
- 433 Figure titles and legends
- 434 Figure 1.
- 435 Title: Summary of study methods and outcomes.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 436 Legend: OMIM=Online Mendelian Inheritance in Man; cSVD=cerebral small vessel disease.
- 437 Created with BioRender.com
- 438 Figure 2.
- 439 Title: Proportion of variant carriers with a phenotype-of-interest.
- 440 Legend: N=total number of variant-carriers; n=number of variant carriers with any phenotype-of-
- 441 interest or stroke.
- 442 Figure 3.
- 443 Title: Association of variant carrier status with phenotype burden.
- 444 Legend: OR=odds ratio; CI=confidence interval; *The association between COL4A1 variant carrier
- 445 status and phenotype score was significant.
- 446 Figure 4.
- 447 Title: COL4A1 leave-one-out analyses.
- 448 Legend: OR=odds ratio; CI=confidence interval; **Association no longer significant.

It is made available under a CC-BY-NC-ND 4.0 International license .

450 Table titles and legends

451 Table 1.

452 Title: Demographic characteristics of UK Biobank participants with WES data.

	All UKB participants with WES	Variant carriers	Non-carriers	n valuo		
	(N=199,313)	(N=1,050)	(N=198,263)	p-value		
Age at last follow up ¹						
Mean (SD)	68.2 (0.018)	67.7 (0.26)	68.2 (0.018)	p=0.43		
Sex						
Female	109,739 (55%)	589 (56%)	109,150 (55%)	p=0.52		
Male	89,574 (45%)	461 (44%)	89,113 (45%)	_ p 0.52		
Townsend Dep	Townsend Deprivation Score					
Mean (SD)	-1.34 (0.01)	-0.44 (0.11)	-1.34 (0.01)	p<2.2x10 ⁻¹⁶		
Self-reported ethnic group ²						
White	187,035 (94%)	783 (75%)	186,252 (94%)	p<2.2x10 ⁻¹⁶		
Non-White	11,319 (6%)	256 (25%)	11,063 (6%)	F ===// -		

453

454

455 Legend: N=number of participants; UKB=UK Biobank; WES=whole exome sequencing; SD=standard

456 deviation; ¹Age at last follow up is the participant's age in March 2020, when the linked health

457 record data is complete from all sources. ²11 variant carriers and 948 non-carriers had missing

458 ethnicity information.

459 Table 2.

460 Title: Variant-carriers in UK Biobank by gene and ethnic group.

It is made available under a CC-BY-NC-ND 4.0 International license .

Gene	Self-reported ethnic group						
	All	White	Black	Asian	Mixed	Other	Unknown
HTRA1	234	229	1	-	-	1	3
		(98%)	(0.4%)			(0.4%)	(1.3%)
COL4A1	481	465 4		5	2	5	-
		(97%)	(0.8%)	(1%)	(0.4%)	(1%)	
COL4A2	336	90	190	3	14	31	8
		(27%)	(57%)	(0.9%)	(4%)	(10%)	(2%)
Any gene-of- interest	1,050	783	195	8	16	37	11

462

463 Legend: 'Other' ethnicity includes Chinese. There was one participant with a variant in both HTRA1

464 and *COL4A1*. There were no participants carrying variants in *TREX1* or *CTSA*.





Figure 2

Association between phenotype score and variant carrier status



Figure 4

Leave-one-out analysis of COL4A1 phenotype score

Hospital admission and death record data-based COL4A1 phenotype score		OR (95% CI)	P value	
No cataract		F4	1.35 (1.06, 1.68)	0.011**
No kidney cyst		·	1.29 (1.07, 1.55)	0.007
No haematuria			1.33 (1.07, 1.62)	0.007
No muscle cramp		∎I	1.28 (1.05, 1.53)	0.01
No myalgia			1.28 (1.06, 1.54)	0.008
No arrhythmia			1.31 (1.07, 1.59)	0.006
No Raynaud's phenomenon		F4	1.31 (1.08, 1.56)	0.005
No haemolytic anaemia			1.28 (1.06, 1.54)	0.009
No migraine		} {	1.24 (1.02, 1.50)	0.03**
No stroke			1.29 (1.05, 1.57)	0.013**
No vascular dementia		}}	1.28 (1.06, 1.54)	0.009
	0.5	1 1.5	2	
		OR (95% CI)		